<html>

<head>
<!-- Document Prepared With E-Services, LLC HTML Software-->
<!-- Copyright 2006 E-Services, LLC.-->
<!-- All rights reserved EDGAR2.com -->



<title>UNITED STATES</title>



</head>

<body lang=EN-US>





<div class=MsoNormal align=center style='text-align:center'>

<p class=MsoNormal align=center style='text-align:center; margin-top:0'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>UNITED STATES</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>SECURITIES AND EXCHANGE COMMISSION</b> </p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>WASHINGTON
DC, 20549</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>_____________</b></p>

<p class=MsoNormal style="margin-top: 0; margin-bottom: 0"><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>FORM 8-K</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>__________________</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>CURRENT REPORT</b></p>

<p class=MsoNormal style="margin-top: 0; margin-bottom: 0"><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>Pursuant to
Section 13 of 15(d) of the Securities Exchange Act of 1934</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>Date of report (date of earliest event reported:&nbsp; April
16, 2007)</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>________________</b></p>

<p class=MsoNormal style="margin-top: 0; margin-bottom: 0"><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>INNOPHOS HOLDINGS, INC.</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>(exact &nbsp;names of registrants
as specified on their charters) </b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>______________________</b></p>
<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'>&nbsp;</p>



<div align="center">

<table class=MsoTableGrid border=0 cellspacing=0 cellpadding=0 width=605
 style='width:6.3in;border-collapse:collapse' id="table2">
 <tr>
  <td width=211 valign=top style='width:2.2in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>Delaware</b></p>
  <p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'>(<font size="2">states or other jurisdictions</font></p>
  <p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'>
	<font size="2">of incorporation)</font></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>001-33124</b></p>
  <p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'>
	<font size="2">(Commission File &nbsp;numbers)</font></p>
  </td>
  <td width=197 valign=top style='width:2.05in;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>20-1380758</b></p>
  <p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'>
	<font size="2">(IRS Employer Identification Nos.)</font></p>
  </td>
 </tr>
</table>

</div>



<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>259 Prospect Plains Road</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>Cranbury,
 New Jersey&nbsp; 08512</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'>
<font size="2">(Address of Principal Executive Officer, including Zip
Code)</font></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>(609) 495-2495</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'>
<font size="2">(Registrants' Telephone Number, Including Area Code)</font></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>
<font size="2">&nbsp;</font></b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'><b>Not Applicable</b></p>

<p class=MsoNormal align=center style='text-align:center; margin-top:0; margin-bottom:0'>
<font size="2">(Former name or former address, if changed since last
report)</font></p>





<p class=MsoNormal style="text-align: left">Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions: </p>
<dir>
	<dir>
		<font FACE="Wingdings">
		<p style="text-align: left">o</font>&nbsp;&nbsp;&nbsp;&nbsp; Written
		communications pursuant to Rule 425 the Securities Act (17 CFR 230.425)
		</p>
		<font FACE="Wingdings">
		<p style="text-align: left">o</font>&nbsp;&nbsp;&nbsp; Soliciting
		material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
		240.14a-12) </p>
		<font FACE="Wingdings">
		<p style="text-align: left">o</font>&nbsp;&nbsp;&nbsp; Pre-commencement
		communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
		240.14d-2(b)</p>
		<font FACE="Wingdings">
		<p style="text-align: left">o</font>&nbsp;&nbsp;&nbsp; Pre-commencement
		communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
		240-13e-4(c)</p>
	</dir>
</dir>





<hr size=2 width="100%" noshade color=navy align=center>

</div>



<br clear=all
style='page-break-before:always'>












<p><b>Item 1.01 Entry into a Material Definitive Agreement.</b> </p>

<p><font size="2">&nbsp;&nbsp; &nbsp; &nbsp; The information
included in Item 2.03 of this Current Report on Form 8&#8722;K is incorporated
by reference into this Item 1.01 of this Current Report on Form 8&#8722;K.
</font> </p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><b>&nbsp;</b></p>

<p class=MsoNormal style='margin-left:.5in;text-indent:-.5in'><b>Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance
Sheet Arrangement of a Registrant</b>.</p>



<p class=MsoNormal><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) On April 16,
2007, the Registrant, or Innophos, issued and sold to qualified institutional
buyers relying on Rule 144A &nbsp;under the Securities Act of 1933, as amended, a
total of $66.0 million in principal amount of its 9<sup>&nbsp;&frac12;</sup> % Senior
Unsecured Notes due 2012, or the Notes. The Notes were sold&nbsp; pursuant to a
Purchase Agreement dated April 11, 2007, or the Purchase Agreement, between
Innophos and Credit Suisse Securities (USA) LLC, or the Initial Purchaser &nbsp;and issued
under the provisions of an Indenture dated as of April 16, 2007, or the Notes
Indenture, between Innophos and U.S. Bank National Association, as trustee, or
the Trustee.&nbsp; . </font> </p>



<p class=MsoNormal><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following
summary description of the Notes and the transaction involving their issuance
and sale is qualified in its entirety by the provisions of the Notes Indenture and
Purchase Agreement, both of which are filed as exhibits to this report and are
herein incorporated by reference:</font></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
 <tr>
  <td valign=top style='width:25%;padding:0in'>
  <p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><b><font size="2">Issuer </font> </b>
	<font size="2">&nbsp;&nbsp; </font> </p>
  </td>
  <td valign=top style='padding:0in 0in 0in 0in'>
  <p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  18.35pt'><font size="2">Innophos Holdings, Inc. </font> </p>
  </td>
 </tr>
 </table>
<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse' id="table1">
	<tr>
		<td valign=top style='width:25%;padding:0in'>&nbsp;</td>
		<td valign=top style='padding:0in 0in 0in 0in'>&nbsp;</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in' height="55">
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><font size="2">&nbsp;<b>Notes Sold </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		</font>
		</p></td>
		<td valign=top style='padding:0in 0in 0in 0in' height="55">
		<p style="text-indent: -12.25pt; margin-left: 12.25pt; margin-right: 0in; margin-top: 0in; margin-bottom: 0" align="left">
		<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; $66.0 million in aggregate principal amount of Notes denominated as: &nbsp;9<sup>&nbsp;1</sup>/2%
		Senior Unsecured Notes due 2012. The Notes were issuable initially in
		minimum denominations of $2,000 and integral multiples of $1,000 in
		registered global form, with specified exceptions. </font> </td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>&nbsp;</td>
		<td valign=top style='padding:0in 0in 0in 0in'>&nbsp;</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><font size="2">&nbsp;<b>Maturity Date </b>
		&nbsp;&nbsp;&nbsp;&nbsp; </font> </p></td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  18.35pt' align="left"><font size="2">April&nbsp;15, 2012.
		</font>
		</p></td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>&nbsp;</td>
		<td valign=top style='padding:0in 0in 0in 0in'>&nbsp;</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><font size="2">&nbsp;<b>Interest </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		</font>
		</p></td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		<p style="margin-right: 0; margin-top: 0; margin-bottom: 0">
		<font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Notes accrue interest from the issue date at a rate of 9<sup>&nbsp;1</sup>/2%
		per annum, payable semi-annually in arrears on April&nbsp;15 and </font> </p>
		<p style="margin-right: 0; margin-top: 0; margin-bottom: 0">
		<font size="2">&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;
		October&nbsp;15
		of each year, commencing&nbsp;October 15, 2007. </font> </td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>&nbsp;</td>
		<td valign=top style='padding:0in 0in 0in 0in'>&nbsp;</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in' height="68">
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><font size="2">&nbsp;<b>Ranking </b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		</font>
		</p></td>
		<td valign=top style='padding:0in 0in 0in 0in' height="68">
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  18.35pt'><font size="2">The Notes are Innophos' unsecured
  obligations and rank equal in the right of payment with all of Innophos'
  future unsecured senior indebtedness; and senior to any future subordinated
  indebtedness of Innophos. The Notes also are effectively subordinated to all
  existing and future indebtedness of Innophos' subsidiaries, including the
  existing senior secured credit facilities and any other secured obligations. &nbsp;</font></p>
		</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>&nbsp;</td>
		<td valign=top style='padding:0in 0in 0in 0in'>&nbsp;</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><b><font size="2">Redemption
		</font>
		</b><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		</font> </p></td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  15.1pt'><font size="2">There is no mandatory redemption or
  sinking fund required for the Notes prior to payment at maturity.&nbsp; </font> </p>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  15.1pt'><font size="2">Innophos may, at its option, redeem
  some or all of the Notes at any time on or after April&nbsp;15, 2009, at
  redemption prices ranging from 102.0 % to 100.0 % depending on the date of
  redemption. &nbsp;</font></p>
		<p style='margin-top:4.5pt;margin-right:0in;margin-bottom:0in;margin-left:
  15.1pt;margin-bottom:.0001pt'><font size="2">In addition, at
  any time prior to April&nbsp;15, 2009, Innophos may, at its option, redeem
  some or all of the Notes at an &quot;applicable premium&quot; (the greater of 1.0% of
  the principal amount or a present value discount calculation provided for in
  the Notes Indenture including accrued interest to the date of redemption).
		</font>
		</p></td>
	</tr>
</table>
<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse'>
	<tr>
		<td valign=top style='width:25%;padding:0in'>&nbsp;</td>
		<td valign=top style='padding:0in 0in 0in 0in'>&nbsp;</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><b><font size="2">Mandatory
  Repurchase Offer </font> </b><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
		</font>
		</p></td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  15.1pt'><font size="2">If Innophos sells certain assets or
  experiences specific kinds of &quot;changes in control,&quot; it must offer to
  repurchase the notes at 101.0% of the aggregate principal amount of notes
  repurchased, plus accrued and unpaid interest, if any, to the date of
  repurchase. Holders of the Notes may, but are not required to, accept the
  offer to repurchase. </font> </p></td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>&nbsp;</td>
		<td valign=top style='padding:0in 0in 0in 0in'>&nbsp;</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><font size="2">&nbsp;<b>Restrictive Covenants </b>
		&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font> </p></td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  18.35pt'><font size="2">The Notes Indenture, among other
  things, restricts the ability of Innophos'&nbsp; and its &quot;restricted subsidiaries&quot;
  to: (1) borrow money or incur other indebtedness; (2) incur liens; (3) pay
  dividends or make other distributions; (4) make other restricted payments and
  investments; (5) issue preferred stock of subsidiaries; (6) enter into
  transactions with affiliates; (7) merge or consolidate; (8) transfer or sell
  assets; and (9) engage in other than permitted business activities.&nbsp; These
  covenants, including related definitions, are set forth in detail and are
  subject to important exceptions and qualifications contained in the Notes
  Indenture.</font></p></td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>&nbsp;</td>
		<td valign=top style='padding:0in 0in 0in 0in'>&nbsp;</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><font size="2">&nbsp;</font><b><font size="2">Events of Default and Remedies</font></b></p></td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		<p style='margin-top:4.5pt;margin-right:0in;margin-bottom:0in;margin-left:
  15.1pt;margin-bottom:.0001pt;page-break-after:avoid'>
		<font size="2">The Notes Indenture &nbsp;also sets forth &nbsp;&quot;events of default<i>,</i>&quot;
  including: (1) default for 30 days in the payment when due of interest on the
  Notes; (2) default in the payment when due of the principal of, or premium,
  if any, on, the Notes; (3) failure by Innophos or any of its restricted
  subsidiaries to comply with specified covenants; (4) failure by Innophos or
  any of its restricted subsidiaries for 45 days after notice to Innophos by
  the Trustee or the holders of at least 25% in aggregate principal amount of
  the Notes to comply with any of the other agreements in the Notes Indenture;
  (5) default under any mortgage, indenture or instrument under which Innophos
  or any of its restricted subsidiaries has borrowed money or guaranteed such a
  borrowing , whether now existing or existing in the future, if that default:
  (a) is a payment default or (b) results in the acceleration of the debt in
  question prior to its express maturity, and all similar defaults involving an
  aggregate of at least $15.0 million; (6) failure by Innophos or any restricted
  subsidiary to pay final judgments (in excess of amounts that Innophos'
  insurance carriers have agreed to pay under applicable policies) aggregating
  in excess of $15.0 million, where the judgments are not paid, discharged or
  stayed for a period of 60 days; and (7) certain events of bankruptcy or
  insolvency described in the Notes Indenture involving Innophos or any of its significant
  restricted subsidiaries.</font></p>
		<p style='margin-top:4.5pt;margin-right:0in;margin-bottom:0in;margin-left:
  15.1pt;margin-bottom:.0001pt;page-break-after:avoid'>
		&nbsp;</p>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  15.1pt'><font size="2">In the case of an event of default
  arising from events of bankruptcy or insolvency, all outstanding Notes become
  due and payable immediately without further action or notice. If any other event
  of default occurs and is continuing, the Trustee or the holders of at least
  25% in aggregate principal amount of the then outstanding Notes may declare
  all the notes to be due and payable immediately. </font> </p>

		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  15.1pt'><font size="2">No individual or entity connected with
  Innophos or its subsidiaries has any personal liability on the Notes.</font></p>
		</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>&nbsp;</td>
		<td valign=top style='padding:0in 0in 0in 0in'>&nbsp;</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><b><font size="2">Amendments
  and Waiver of Notes Indenture</font></b></p></td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		<p style='margin-top:4.5pt;margin-right:0in;margin-bottom:0in;margin-left:
  15.1pt;margin-bottom:.0001pt'><font size="2">With specific &nbsp;exceptions,
  the Notes Indenture or the Notes may be amended or supplemented with the
  consent of the holders of at least a majority in aggregate principal amount
  of the Notes then outstanding (including consents obtained in connection with
  a purchase of, or tender offer for, Notes), and any existing default or event
  of default or compliance with any provision of the Notes Indenture or the
  Notes may be waived with the consent of the holders of a like majority.
		</font>
		</p>
		<p style='margin-top:4.5pt;margin-right:0in;margin-bottom:0in;margin-left:
  15.1pt;margin-bottom:.0001pt;page-break-after:avoid'>
		&nbsp;</p></td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		&nbsp;</td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		&nbsp;</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><b><font size="2">Trustee
		</font>
		</b></p></td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  18.35pt'><font size="2">U.S. Bank National Association</font></p>

		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  18.35pt'><font size="2">The Notes Indenture contains
  provisions regulating the relationships the Trustee can have with Innophos
  and its affiliates and governing the exercise of the Trustee's powers. &nbsp;</font></p>
		</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		&nbsp;</td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		&nbsp;</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		</td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><b><font size="2">Transfer
  Restrictions</font></b></p></td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  18.35pt'><font size="2">The Notes were not registered under
  the Securities Act or any state securities laws and may not be offered or
  sold in the United States absent registration under the Securities Act and
  applicable state securities laws or applicable exemptions from registration
  requirements., Innophos is not required to, and does not intend to, make any
  offer to exchange the Notes for notes registered under the Securities Act or
  to otherwise register the Notes for resale under the Securities Act.
		</font>
		</p></td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>&nbsp;</td>
		<td valign=top style='padding:0in 0in 0in 0in'>&nbsp;</td>
	</tr>
	<tr>
		<td valign=top style='width:25%;padding:0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  12.25pt;text-indent:-12.25pt'><font size="2">&nbsp;<b>Use of Proceeds </b>
		&nbsp; </font> </p></td>
		<td valign=top style='padding:0in 0in 0in 0in'>
		<p style='margin-top:0in;margin-right:0in;margin-bottom:.75pt;margin-left:
  18.35pt'><font size="2">The &nbsp;proceeds from the sale of the Notes,
  together with cash on hand, were applied to pay expenses and redeem the
  entire remaining outstanding amount of Floating Rate Senior Notes due 2015 (including
  the payment of principal, premium and accrued interest) issued by Innophos'
  wholly-owned subsidiary, Innophos Investments Holdings, Inc. See Item 8.01 of
  this report. </font> </p></td>
	</tr>
</table>

<p class=MsoNormal><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Notes were
sold to the Initial Purchaser in accordance with the Purchase Agreement. In
that agreement, Innophos and the Initial Purchaser made a number of customary representations,
warranties and agreements &nbsp;to and with each other about the Notes, the manner
in which they were being sold and could be resold, the nature of Innophos'
business and matters affecting it, and certain other matters . &nbsp;</font></p>

<p class=MsoNormal><b>Item 8.01 Other Items</b><b>.
</b></p>

<p class=MsoNormal><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font size="2">&nbsp;
</font> </b><font size="2">On April 17, 2007, Innophos issued a press release
concerning its issuance of the Notes and the use of proceeds from that
transaction by its wholly-owned subsidiary, Innophos Investments Holdings,
Inc., or Investments, to call for redemption on May 17, 2007 the remaining $60.8million
in principal amount of Investments' Floating Rate Senior Notes due 2015, or
Floating Rate Notes. In connection with the call, the full amount required for
the redemption of the Floating Rate Notes (principal, premium and accrued
interest) was irrevocably deposited with the Trustee, satisfying the conditions
precedent for releasing and discharging Investments under the terms of the&nbsp;
indenture governing the Floating Rate Notes. The text of the press release is
filed with this report as Exhibit 99.1 and is incorporated by reference in
response to this item.</font></p>



<p class=MsoNormal><b>Item 9.01 Financial Statements and Exhibits</b></p>

<p class=MsoNormal><font size="2">(d) Exhibits </font> </p>



<p class=MsoNormal><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following
exhibits are filed with this report:</font></p>

<p class=MsoNormal><b><font size="2">Exhibit
No. </font><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font> <u><font size="2">Description</font></u></b></p>

<p class=MsoNormal style='margin-left:1.5in;text-indent:-1.5in'><font size="2">4.1<b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </b>Form of Indenture dated as of April 16, 2007 between
Innophos Holdings, Inc. and U.S. Bank National Association</font></p>



<p class=MsoNormal style='margin-left:1.5in;text-indent:-1.5in'><font size="2">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form of
Purchase Agreement dated April 11, 2007 between Innophos Holdings, Inc. and
Credit Suisse Securities (USA) LLC</font></p>



<p class=MsoNormal style='margin-left:1.5in;text-indent:-107.95pt'>
<font size="2">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Press
release dated April 17, 2007 issued by Innophos Holdings, Inc. relating to issuance
of $66.0 million 9.5% Senior Unsecured Notes due 2012 and redemption by
Innophos Investments Holdings, Inc. of remaining $60.8 million Floating Rate
Senior notes due 2015</font></p>



<div class=MsoNormal align=center style='text-align:center'>

<hr size=2 width="100%" noshade color=navy align=center>

</div>



<br clear=all
style='page-break-before:always'>










<p class=MsoNormal style='margin-left:1.5in;text-indent:-107.95pt'><b>&nbsp;</b></p>

<p class=MsoNormal align=center style='text-align:center'><b>SIGNATURES</b></p>



<p class=MsoNormal><font size="2">According to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned, hereunto duly authorized.
</font>
</p>



<p class=MsoNormal style="margin-top: 0; margin-bottom: 0"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font></p>
<p class=MsoNormal style="margin-top: 0; margin-bottom: 0"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font>
<b><font size="2">INNOPHOS HOLDINGS, INC. </font> </b></p>

<p class=MsoNormal style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p class=MsoNormal style="margin-top: 0; margin-bottom: 0">&nbsp;</p>

<p class=MsoNormal style="margin-top: 0; margin-bottom: 0"><font size="2">Dated:&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; April 17,
2007&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; By:&nbsp;
</font> <u><font size="2">/s/ Mark Feuerbach&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></u></p>

<p class=MsoNormal style="margin-top: 0; margin-bottom: 0"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Name:
Mark Feuerbach</font></p>

<p class=MsoNormal style="margin-top: 0; margin-bottom: 0"><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Title:&nbsp;&nbsp; Vice President -Treasury,&nbsp; Financial Planning and
Analysis
</font>
</p>

<p class=MsoNormal style='margin-left:2.0in;text-indent:-2.0in'><font size="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font></p>



</body>

</html>
[{"type": "8-K", "sequence": "1", "filename": "in8k041607final1.htm", "description": "INNOPHOS HOLDINGS, INC - 8-K", "secsgml_size_bytes": 31874}]
{"company-data": {"conformed-name": "Innophos Holdings, Inc.", "cik": "0001364099", "assigned-sic": "5160", "irs-number": "201380758"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33124", "film-number": "07771607"}, "business-address": {"street1": "259 PROSPECT PLAINS ROAD", "city": "CRANBURY", "state": "NJ", "zip": "08512", "phone": "(609) 495 2495"}, "mail-address": {"street1": "259 PROSPECT PLAINS ROAD", "city": "CRANBURY", "state": "NJ", "zip": "08512"}}
UNITED STATES
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON
DC, 20549
_____________
FORM 8-K
__________________
CURRENT REPORT
Pursuant to
Section 13 of 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported:  April
16, 2007)
________________
INNOPHOS HOLDINGS, INC.
(exact  names of registrants
as specified on their charters)
______________________
Delaware
(
states or other jurisdictions
of incorporation)
001-33124
(Commission File  numbers)
20-1380758
(IRS Employer Identification Nos.)
259 Prospect Plains Road
Cranbury,
 New Jersey  08512
(Address of Principal Executive Officer, including Zip
Code)
(609) 495-2495
(Registrants' Telephone Number, Including Area Code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
o
Written
		communications pursuant to Rule 425 the Securities Act (17 CFR 230.425)
o
Soliciting
		material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
		240.14a-12)
o
Pre-commencement
		communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
		240.14d-2(b)
o
Pre-commencement
		communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
		240-13e-4(c)
Item 1.01 Entry into a Material Definitive Agreement.
The information
included in Item 2.03 of this Current Report on Form 8−K is incorporated
by reference into this Item 1.01 of this Current Report on Form 8−K.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance
Sheet Arrangement of a Registrant
.
(a) On April 16,
2007, the Registrant, or Innophos, issued and sold to qualified institutional
buyers relying on Rule 144A  under the Securities Act of 1933, as amended, a
total of $66.0 million in principal amount of its 9
½
% Senior
Unsecured Notes due 2012, or the Notes. The Notes were sold  pursuant to a
Purchase Agreement dated April 11, 2007, or the Purchase Agreement, between
Innophos and Credit Suisse Securities (USA) LLC, or the Initial Purchaser  and issued
under the provisions of an Indenture dated as of April 16, 2007, or the Notes
Indenture, between Innophos and U.S. Bank National Association, as trustee, or
the Trustee.  .
The following
summary description of the Notes and the transaction involving their issuance
and sale is qualified in its entirety by the provisions of the Notes Indenture and
Purchase Agreement, both of which are filed as exhibits to this report and are
herein incorporated by reference:
Issuer
Innophos Holdings, Inc.
Notes Sold
$66.0 million in aggregate principal amount of Notes denominated as:  9
1
/2%
		Senior Unsecured Notes due 2012. The Notes were issuable initially in
		minimum denominations of $2,000 and integral multiples of $1,000 in
		registered global form, with specified exceptions.
Maturity Date
April 15, 2012.
Interest
The Notes accrue interest from the issue date at a rate of 9
1
/2%
		per annum, payable semi-annually in arrears on April 15 and
October 15
		of each year, commencing October 15, 2007.
Ranking
The Notes are Innophos' unsecured
  obligations and rank equal in the right of payment with all of Innophos'
  future unsecured senior indebtedness; and senior to any future subordinated
  indebtedness of Innophos. The Notes also are effectively subordinated to all
  existing and future indebtedness of Innophos' subsidiaries, including the
  existing senior secured credit facilities and any other secured obligations.
Redemption
There is no mandatory redemption or
  sinking fund required for the Notes prior to payment at maturity.
Innophos may, at its option, redeem
  some or all of the Notes at any time on or after April 15, 2009, at
  redemption prices ranging from 102.0 % to 100.0 % depending on the date of
  redemption.
In addition, at
  any time prior to April 15, 2009, Innophos may, at its option, redeem
  some or all of the Notes at an "applicable premium" (the greater of 1.0% of
  the principal amount or a present value discount calculation provided for in
  the Notes Indenture including accrued interest to the date of redemption).
Mandatory
  Repurchase Offer
If Innophos sells certain assets or
  experiences specific kinds of "changes in control," it must offer to
  repurchase the notes at 101.0% of the aggregate principal amount of notes
  repurchased, plus accrued and unpaid interest, if any, to the date of
  repurchase. Holders of the Notes may, but are not required to, accept the
  offer to repurchase.
Restrictive Covenants
The Notes Indenture, among other
  things, restricts the ability of Innophos'  and its "restricted subsidiaries"
  to: (1) borrow money or incur other indebtedness; (2) incur liens; (3) pay
  dividends or make other distributions; (4) make other restricted payments and
  investments; (5) issue preferred stock of subsidiaries; (6) enter into
  transactions with affiliates; (7) merge or consolidate; (8) transfer or sell
  assets; and (9) engage in other than permitted business activities.  These
  covenants, including related definitions, are set forth in detail and are
  subject to important exceptions and qualifications contained in the Notes
  Indenture.
Events of Default and Remedies
The Notes Indenture  also sets forth  "events of default
,
"
  including: (1) default for 30 days in the payment when due of interest on the
  Notes; (2) default in the payment when due of the principal of, or premium,
  if any, on, the Notes; (3) failure by Innophos or any of its restricted
  subsidiaries to comply with specified covenants; (4) failure by Innophos or
  any of its restricted subsidiaries for 45 days after notice to Innophos by
  the Trustee or the holders of at least 25% in aggregate principal amount of
  the Notes to comply with any of the other agreements in the Notes Indenture;
  (5) default under any mortgage, indenture or instrument under which Innophos
  or any of its restricted subsidiaries has borrowed money or guaranteed such a
  borrowing , whether now existing or existing in the future, if that default:
  (a) is a payment default or (b) results in the acceleration of the debt in
  question prior to its express maturity, and all similar defaults involving an
  aggregate of at least $15.0 million; (6) failure by Innophos or any restricted
  subsidiary to pay final judgments (in excess of amounts that Innophos'
  insurance carriers have agreed to pay under applicable policies) aggregating
  in excess of $15.0 million, where the judgments are not paid, discharged or
  stayed for a period of 60 days; and (7) certain events of bankruptcy or
  insolvency described in the Notes Indenture involving Innophos or any of its significant
  restricted subsidiaries.
In the case of an event of default
  arising from events of bankruptcy or insolvency, all outstanding Notes become
  due and payable immediately without further action or notice. If any other event
  of default occurs and is continuing, the Trustee or the holders of at least
  25% in aggregate principal amount of the then outstanding Notes may declare
  all the notes to be due and payable immediately.
No individual or entity connected with
  Innophos or its subsidiaries has any personal liability on the Notes.
Amendments
  and Waiver of Notes Indenture
With specific  exceptions,
  the Notes Indenture or the Notes may be amended or supplemented with the
  consent of the holders of at least a majority in aggregate principal amount
  of the Notes then outstanding (including consents obtained in connection with
  a purchase of, or tender offer for, Notes), and any existing default or event
  of default or compliance with any provision of the Notes Indenture or the
  Notes may be waived with the consent of the holders of a like majority.
Trustee
U.S. Bank National Association
The Notes Indenture contains
  provisions regulating the relationships the Trustee can have with Innophos
  and its affiliates and governing the exercise of the Trustee's powers.
Transfer
  Restrictions
The Notes were not registered under
  the Securities Act or any state securities laws and may not be offered or
  sold in the United States absent registration under the Securities Act and
  applicable state securities laws or applicable exemptions from registration
  requirements., Innophos is not required to, and does not intend to, make any
  offer to exchange the Notes for notes registered under the Securities Act or
  to otherwise register the Notes for resale under the Securities Act.
Use of Proceeds
The  proceeds from the sale of the Notes,
  together with cash on hand, were applied to pay expenses and redeem the
  entire remaining outstanding amount of Floating Rate Senior Notes due 2015 (including
  the payment of principal, premium and accrued interest) issued by Innophos'
  wholly-owned subsidiary, Innophos Investments Holdings, Inc. See Item 8.01 of
  this report.
The Notes were
sold to the Initial Purchaser in accordance with the Purchase Agreement. In
that agreement, Innophos and the Initial Purchaser made a number of customary representations,
warranties and agreements  to and with each other about the Notes, the manner
in which they were being sold and could be resold, the nature of Innophos'
business and matters affecting it, and certain other matters .
Item 8.01 Other Items
.
On April 17, 2007, Innophos issued a press release
concerning its issuance of the Notes and the use of proceeds from that
transaction by its wholly-owned subsidiary, Innophos Investments Holdings,
Inc., or Investments, to call for redemption on May 17, 2007 the remaining $60.8million
in principal amount of Investments' Floating Rate Senior Notes due 2015, or
Floating Rate Notes. In connection with the call, the full amount required for
the redemption of the Floating Rate Notes (principal, premium and accrued
interest) was irrevocably deposited with the Trustee, satisfying the conditions
precedent for releasing and discharging Investments under the terms of the 
indenture governing the Floating Rate Notes. The text of the press release is
filed with this report as Exhibit 99.1 and is incorporated by reference in
response to this item.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following
exhibits are filed with this report:
Exhibit
No.
Description
4.1
Form of Indenture dated as of April 16, 2007 between
Innophos Holdings, Inc. and U.S. Bank National Association
4.2                                           Form of
Purchase Agreement dated April 11, 2007 between Innophos Holdings, Inc. and
Credit Suisse Securities (USA) LLC
99.1                                         Press
release dated April 17, 2007 issued by Innophos Holdings, Inc. relating to issuance
of $66.0 million 9.5% Senior Unsecured Notes due 2012 and redemption by
Innophos Investments Holdings, Inc. of remaining $60.8 million Floating Rate
Senior notes due 2015
SIGNATURES
According to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this
report to be signed on its behalf by the undersigned, hereunto duly authorized.
INNOPHOS HOLDINGS, INC.
Dated:              April 17,
2007                                             By:
/s/ Mark Feuerbach
Name:
Mark Feuerbach
Title:   Vice President -Treasury,  Financial Planning and
Analysis